Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma

Melanoma Research

Volumn 15, Issue 6, 2005, Pages 495-502

  Ordonez, Jose L ^a   Paraoan, Luminita ^a   Hiscott, Paul ^a   Gray, Donna ^a   García Fiñana, Marta ^a   Grierson, Ian ^a   Damato, Bertil ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Matricellular; Secreted Protein Acidic and Rich in Cysteine (SPARC); Thrombospondin; Uveal melanoma

Indexed keywords

OSTEONECTIN; PARAFFIN; REGULATOR PROTEIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THROMBOSPONDIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; EMBEDDING; EPITHELIUM TUMOR; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAMPLE; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR VASCULARIZATION; UVEA MELANOMA; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CHOROID TUMOR; MELANOMA; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CHOROID NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OSTEONECTIN; THROMBOSPONDIN 1; THROMBOSPONDINS; TUMOR CELLS, CULTURED;

EID: 33646967516     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200512000-00003     Document Type: Article

References (39)

1. Damato BE. Uveal melanoma. In: Damato BE, editor. Ocular Tumours: Diagnosis and Treatment. Oxford: Butterworth-Heinemann; 2000, pp. 57-93.
2. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14:608-616.
3. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 2003; 278:37 849-37 857.
4. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001; 107:929-934.
5. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001; 19:816-827.
6. Jendraschak E, Sage EH. Regulation of angiogenesis by SPARC and angiostatin: implications for tumour cell biology. Semin Cancer Biol 1996; 7:139-146.
7. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22:63-71.
8. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981; 26:99-105.
9. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 130:503-506.
10. Lawler J, Detmar M. Tumour progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004; 36:1038-1045.
11. Rofstad EK, Galappathi K, Mathiesen B. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumour in human melanoma xenografts. Int J Radiat Oncol Biol Phys 2004; 58:493-499.
12. Trotter MJ, Colwell R, Tron VA. Thrombospondin-1 and cutaneous melanoma. J Cutan Med Surg 2003; 7:136-141.
13. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108:210-214.
14. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30:339-344.
15. Rumpler G, Becker B, Hafner C, McClelland M, Stolz W, Landthaler M, et al. Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol 2003; 12:761-771.
16. Damato B. Time to treatment of uveal melanoma in the United Kingdom. Eye 2001; 15:155-158.
17. Rhee DJ, Fariss RN, Brekken R, Sage EH, Russell P. The matricellular protein SPARC is expressed in human trabecular meshwork. Exp Eye Res 2003; 77:601-607.
18. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45:1117-1124.
19. Hiscott P, Hagan S, Heathcote L, Sheridan CM, Groenewald CP, Grierson I, et al. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye 2002; 16:393-403.
20. Armstrong DJ, Hiscott P, Batterbury M, Kaye S. Keratocyte matrix interactions and thrombospondin 2. Mol Vis 2003; 9:74-79.
21. Hiscott P, Sorokin L, Schlotzer-Schrehardt U, Bluthner K, Endress K, Mayer U. Expression of thrombospondin 1 by adult lens epithelium. Exp Eye Res 1996; 62:709-712.
22. Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 1997; 81:240-246.
23. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999; 40:2471-2480.
24. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumour growth and angiogenesis. Proc Natl Acad Sci USA 1999; 96:14 888-14 893.
25. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049-1054.
26. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992; 89:1281-1285.
27. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14:3977-3988.
28. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47:1495-1506.
29. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002; 21:7077-7091.
30. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995; 43:791-800.
31. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36:1070-1078.
32. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumour growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98:12 485-12 490.
33. Li K, Yang M, Yuen PM, Chik KW, Li CK, Shing MM, et al. Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int J Mol Med 2003; 12:995-1001.
34. Uray IP, Liang Y, Hyder SM. Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Lett 2004; 207:101-107.
35. Daniels KJ, Boldt HC, Martin JA, Gardner LM, Meyer M, Folberg R. Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumour progression. Lab Invest 1996; 75:55-66.
36. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-752.
37. Massi D, Franchi A, Paglierani M, Ketabchi S, Borgognoni L, Reali UM, et al. Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma. Hum Pathol 2004; 35:496-502.
38. Gietema JA, de Vries EG. Clinical cancer research 2002: new agents and therapies. Drug Resist Update 2002; 5:192-203.
39. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3:171-176.